RXRX
HealthcareRecursion Pharmaceuticals, Inc.
$4.37
+$0.17 (+4.05%)
Jan 5, 2026
Price History (1Y)
Analysis
Recursion Pharmaceuticals, Inc. operates within the healthcare sector and biotechnology industry, employing approximately 800 individuals. The company's market capitalization stands at $2.28 billion. The company's financial health is characterized by significant losses, with a net income of -$715.54 million and EBITDA of -$637.87 million over the trailing twelve months. Gross margin and profit margin are both 0.0%, indicating that revenue does not cover operational costs. Return on equity stands at -91.1% and return on assets is -42.0%. The company has a debt-to-equity ratio of 7.87 and cash reserves of $659.84 million, with $82.37 million in outstanding debt. The valuation context for Recursion Pharmaceuticals, Inc. includes an unreported price-to-earnings (P/E) ratio over the trailing twelve months, but its forward P/E is -3.65. Price to book stands at 2.05 and price to sales is 52.14. The company's revenue growth over the past year was -80.2%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Visit website →Key Statistics
- Market Cap
- $2.28B
- P/E Ratio
- N/A
- 52-Week High
- $12.36
- 52-Week Low
- $3.79
- Avg Volume
- 40.62M
- Beta
- 0.95
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 800